Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
| 0.44 | |
| 0.477 | |
| - | |
| 0.4993 | |
| 0.43 | |
| 0.43-398.4 | |
| 1 347 K | |
| 2 860 K | |
| 1 974 K | |
| -1.6384 | |
| 1.888 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there’s still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketami...
In this article, we discuss 11 of the best psychedelic stocks to buy in 2024. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy. Unlike substances like mari...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
